Etienna Bio, Inc. is an early-stage biotechnology company developing autologous, cell-enabled biomaterials for regenerative and aesthetic applications. The company is pioneering a first-in-class autologous cell-technology platform capable of generating both adipocytes and collagen-producing cells from less than one gram of a patient’s own tissue, enabling living, natural, and durable aesthetic outcomes. Unlike competitors focused on single products or narrow indications, Etienna’s modular platform intersects across four major aesthetic and reconstructive markets: facial fillers, breast augmentation, reconstruction, and fat transfer. Etienna holds exclusive global rights to intellectual property covering human adipose-derived progenitor cells combined with an adipose-derived hydrogel matrix, supporting the development of novel, autologous, cell-enabled products for non-therapeutic regenerative and aesthetic indications.